A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines
Daniela Peruzzi, Sridhar Dharmapuri, Agostino Cirillo, Bruno Ercole Bruni, Alfredo Nicosia, Riccardo Cortese, Stefano Colloca, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio, Daniela Peruzzi, Sridhar Dharmapuri, Agostino Cirillo, Bruno Ercole Bruni, Alfredo Nicosia, Riccardo Cortese, Stefano Colloca, Gennaro Ciliberto, Nicola La Monica, Luigi Aurisicchio
Abstract
The use of adenovirus (Ad) as vaccine vectors is hindered by pre-existing immunity to human Ads in most of the human population. In order to overcome this limitation, uncommon alternative Ad serotypes need to be utilized. In this study, an E1-E3 deleted recombinant Ad based on the chimpanzee serotype 3 (ChAd3) was engineered to express human carcinoembryonic antigen (CEA) protein or rat neu extracellular/transmembrane domains (ECD.TM). ChAd3 vectors were tested in CEA transgenic (CEA.Tg) and BALB/NeuT mice, which show immunologic tolerance to these antigens. ChAd3 is capable of inducing an immune response comparable to that of hAd5 serotype-based vectors, thus breaking tolerance to tumor associated antigens (TAAs) and achieving anti-tumor effects. Of importance is that ChAd3 can overcome hAd5 pre-existing immunity and work in conjunction with DNA electroporation (DNA-EP) and other Ad vaccines based on common human serotypes.
Figures
References
- Wold W.S.M., Tollefson A.E.E. 2nd ed. Humana Press; 2007. Adenovirus methods and protocols adenoviruses, Ad vectors, quantitation, and animal models.
- Hierholzer J.C., Wigand R., Anderson L.J., Adrian T., Gold J.W. Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43–47) J Infect Dis. 1988;158(4):804–813.
- Schnurr D., Dondero M.E. Two new candidate adenovirus serotypes. Intervirology. 1993;36(2):79–83.
- De Jong J.C., Wermenbol A.G., Verweij-Uijterwaal M.W., Slaterus K.W., Wertheim-Van Dillen P., Van Doornum G.J. Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol. 1999;37(12):3940–3945.
- Jager L., Ehrhardt A. Emerging adenoviral vectors for stable correction of genetic disorders. Curr Gene Ther. 2007;7(4):272–283.
- Hartman Z.C., Appledorn D.M., Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 2008;132(1–2):1–14.
- He Z., Wlazlo A.P., Kowalczyk D.W., Cheng J., Xiang Z.Q., Giles-Davis W. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology. 2000;270(1):146–161.
- Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 1996;219(1):220–227.
- Tims T., Briggs D.J., Davis R.D., Moore S.M., Xiang Z., Ertl H.C. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine. 2000;18(25):2804–2807.
- Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science. 2006;312(5779):1530–1533.
- Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415(6869):331–335.
- Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature. 2003;424(6949):681–684.
- Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008;46(11):1769–1781.
- Cox K.S., Clair J.H., Prokop M.T., Sykes K.J., Dubey S.A., Shiver J.W. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles. J Virol. 2008;82(16):8161–8171.
- Casimiro D.R., Chen L., Fu T.M., Evans R.K., Caulfield M.J., Davies M.E. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77(11):6305–6313.
- Fitzgerald J.C., Gao G.P., Reyes-Sandoval A., Pavlakis G.N., Xiang Z.Q., Wlazlo A.P. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003;170(3):1416–1422.
- Roberts D.M., Nanda A., Havenga M.J., Abbink P., Lynch D.M., Ewald B.A. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006;441(7090):239–243.
- Kresge K.J. Renewed promise. Annual AIDS vaccine meeting highlights recent data from clinical trials and lessons on recruitment and retention of volunteers. IAVI Rep. 2005;9(4):18–20.
- Guibinga G.H., Lochmuller H., Massie B., Nalbantoglu J., Karpati G., Petrof B.J. Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. J Virol. 1998;72(6):4601–4609.
- Ye X., Robinson M.B., Pabin C., Batshaw M.L., Wilson J.M. Transient depletion of CD4 lymphocyte improves efficacy of repeated administration of recombinant adenovirus in the ornithine transcarbamylase deficient sparse fur mouse. Gene Ther. 2000;7(20):1761–1767.
- Singh R., Tian B., Kostarelos K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J. 2008;22(9):3389–3402.
- Sakurai F., Kawabata K., Mizuguchi H. Adenovirus vectors composed of subgroup B adenoviruses. Curr Gene Ther. 2007;7(4):229–238.
- Fattori E., Zampaglione I., Arcuri M., Meola A., Ercole B.B., Cirillo A. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes. Gene Ther. 2006;13(14):1088–1096.
- Douglas J.T., Miller C.R., Kim M., Dmitriev I., Mikheeva G., Krasnykh V. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol. 1999;17(5):470–475.
- Belousova N., Krendelchtchikova V., Curiel D.T., Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol. 2002;76(17):8621–8631.
- Sarkioja M., Pesonen S., Raki M., Hakkarainen T., Salo J., Ahonen M.T. Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies. Gene Ther. 2008;15(12):921–929.
- Sailaja G., HogenEsch H., North A., Hays J., Mittal S.K. Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther. 2002;9(24):1722–1729.
- Barouch D.H., Pau M.G., Custers J.H., Koudstaal W., Kostense S., Havenga M.J. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 2004;172(10):6290–6297.
- Lemckert A.A., Sumida S.M., Holterman L., Vogels R., Truitt D.M., Lynch D.M. Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol. 2005;79(15):9694–9701.
- Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med. 2004;55:355–372.
- Bangari D.S., Mittal S.K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 2006;24(7):849–862.
- Wuest T., Both G.W., Prince A.M., Hofmann C., Loser P. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine. 2004;22(21–22):2717–2721.
- McCoy K., Tatsis N., Korioth-Schmitz B., Lasaro M.O., Hensley S.E., Lin S.W. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81(12):6594–6604.
- Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006;13(5):421–429.
- Zhi Y., Figueredo J., Kobinger G.P., Hagan H., Calcedo R., Miller J.R. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther. 2006;17(5):500–506.
- Zhou D., Cun A., Li Y., Xiang Z., Ertl H.C. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther. 2006;14(5):662–672.
- Perreau M., Mennechet F., Serratrice N., Glasgow J.N., Curiel D.T., Wodrich H. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol. 2007;81(7):3272–3284.
- Perreau M., Kremer E.J. Frequency, proliferation, and activation of human memory T cells induced by a nonhuman adenovirus. J Virol. 2005;79(23):14595–14605.
- Bangari D.S., Mittal S.K. Porcine adenoviral vectors evade preexisting humoral immunity to adenoviruses and efficiently infect both human and murine cells in culture. Virus Res. 2004;105(2):127–136.
- Ryan S.O., Gantt K.R., Finn O.J. Tumor antigen-based immunotherapy and immunoprevention of cancer. Int Arch Allergy Immunol. 2007;142(3):179–189.
- Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum Gene Ther. 2006;17(1):81–92.
- Facciabene A., Aurisicchio L., Elia L., Palombo F., Mennuni C., Ciliberto G. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine. 2007;26(1):47–58.
- Gallo P., Dharmapuri S., Nuzzo M., Maldini D., Cipriani B., Forni G. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice. Int J Cancer. 2007;120(3):574–584.
- Mennuni C., Calvaruso F., Facciabene A., Aurisicchio L., Storto M., Scarselli E. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer. 2005;117(3):444–455.
- Aurisicchio L., Mennuni C., Giannetti P., Calvaruso F., Nuzzo M., Cipriani B. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer. 2007;120(11):2290–2300.
- Yang Z.-Y., Wyatt L.S., Kong W.-P., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol. 2003;77:799–803.
- Thompson J.A. Carcinoembryonic antigen gene family: molecular biology and clinical perspective. J Clin Lab Anal. 1991;5:344.
- Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182.
- Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712.
- Cipriani B., Fridman A., Bendtsen C., Dharmapuri S., Mennuni C., Pak I. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum Gene Ther. 2008;19(7):670–680.
- Lucchini F., Sacco M.G., Hu N., Villa A., Brown J., Cesano L. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett. 1992;64(3):203–209.
- UKCCR Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia second edition, London, WC2A 3PX. Br J Cancer. 1998
- Giannetti P., Facciabene A., La Monica N., Aurisicchio L. Individual mouse analysis of the cellular immune response to tumor antigens in peripheral blood by intracellular staining for cytokines. J Immunol Methods. 2006;316(1–2):84–96.
- Aste-Amezaga M., Bett A.J., Wang F., Casimiro D.R., Antonello J.M., Patel D.K. Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther. 2004;15(3):293–304.
- Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. Br J Biomed Sci. 1999;56(3):209–214.
- Eades-Perner A.M., van der Putten H., Hirth A., Thompson J., Neumaier M., von Kleist S. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 1994;54(15):4169–4176.
- Hance K.W., Zeytin H.E., Greiner J.W. Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines. Mutat Res. 2005;576(1–2):132–154.
- Coyne C.B., Bergelson J.M. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev. 2005;57(6):869–882.
- Dechecchi M.C., Melotti P., Bonizzato A., Santacatterina M., Chilosi M., Cabrini G. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol. 2001;75(18):8772–8780.
- Baker A.H., McVey J.H., Waddington S.N., Di Paolo N.C., Shayakhmetov D.M. The influence of blood on in vivo adenovirus bio-distribution and transduction. Mol Ther. 2007;15(8):1410–1416.
- Waddington S.N., McVey J.H., Bhella D., Parker A.L., Barker K., Atoda H. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3):397–409.
- Liu J., O’Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009;457(7225):87–91.
- Roy S., Kobinger G.P., Lin J., Figueredo J., Calcedo R., Kobasa D. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007;25(39–40):6845–6851.
Source: PubMed